NETAG issues appraisal and recommendation on aflibercept for AMD

Source: NETAG Area: Evidence > Drug Specific Reviews The NHS North East Treatment Advisory Group (NETAG) has undertaken an appraisal of aflibercept (Eylea®) within its licensed indication for the management of neovascular (wet) age-related macular degeneration (AMD). The Group recommends its use, within its licensed indication, for the treatment of newly diagnosed and untreated wet AMD. It does not however recommend its use for the same episode of AMD refractory to treatment with other biological therapies such as ranibizumab. This recommendation is contingent on a maximum cost per aflibercept dose as stated in the associated appraisal report.   This recommendation with be superseded by a recommendation from NICE, due to be published in August 2013.   The recommendation and associated appraisal report are available from the NETAG website at the links below.
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news